Ocrevus market report sees growth on rising MS cases and personalized care

The Business Research Company’s new report projects continued expansion in the global Ocrevus market through 2035, driven by rising multiple sclerosis diagnoses, broader infusion access and growing interest in personalized treatment. North America held the largest share in 2025, while monoclonal antibody and B-cell targeted therapies remain key trends.

Why it matters: - Ocrevus sits in a growing multiple sclerosis treatment market where more patients, more diagnosis and more treatment options are pushing demand higher. - The report points to a shift toward personalized medicine, home and outpatient infusion services, and next-generation monoclonal antibodies as the biggest commercial forces ahead. - Better long-term disease control remains a core driver for providers and patients managing chronic MS.

What happened: - The Business Research Company released its Ocrevus Global Market Report 2026, covering market size, trends and forecasts through 2035. - The report says North America held the largest share of the Ocrevus market in 2025. - The report also covers Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East and Africa. - A free sample of the report is available here. - The full report is available here.

The details: - Ocrevus is a prescription monoclonal antibody used for relapsing-remitting multiple sclerosis, active secondary progressive multiple sclerosis and primary progressive multiple sclerosis. - The drug targets and depletes CD20-positive B-cells, which helps reduce immune damage to nerve cells. - The report links historical market growth to better understanding of MS pathology, approval of disease-modifying therapies, expanded neurology specialty care, rising diagnosis rates and wider access to biologic infusion infrastructure. - Forecast growth is tied to more personalized MS treatment, expansion of home and outpatient infusion services and higher investment in neuroimmunology research. - The report flags rising use of monoclonal antibody therapies, broader B-cell targeted treatment adoption, growth in infusion center-based care, stronger focus on long-term disease modification and more real-world evidence gathering. - The report says the global MS burden is rising, which supports demand for Ocrevus. - The MS Society UK said in May 2024 that more than 150,000 people in the UK are living with MS. - The MS Society UK also reported prevalence increases of 15% in England, 10% in Scotland, 9% in Northern Ireland and 8% in Wales. - The report says personalized medicine is accelerating because providers can tailor treatment using genetic information and diagnostic advances. - The Personalized Medicine Coalition said in February 2024 that the FDA approved 16 new personalized treatments for rare diseases in 2023, up from six in 2022. - The Business Research Company said its 2026 market reports now include expanded strategic intelligence, market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspot infographics, and key technology and future trend analysis.

Between the lines: - The report frames Ocrevus as part of a broader move in neurology toward targeted biologic therapy rather than one-size-fits-all treatment. - North America’s lead suggests the strongest near-term revenue base is still in markets with established infusion access and specialist care. - The emphasis on home and outpatient infusion points to cost, convenience and capacity pressures shaping how MS care is delivered.

What's next: - The report expects continued market growth through 2035 as personalized care and infusion access broaden. - Further adoption of B-cell targeted therapy and long-term disease management tools is likely to shape the next phase of competition. - Regional growth outside North America will depend on healthcare infrastructure, disease prevalence and access to advanced therapies.

The bottom line: - Ocrevus is positioned to benefit from rising MS prevalence and a treatment shift toward personalized, targeted and more convenient care delivery.